Published in Trends Pharmacol Sci on June 01, 2005
Cleveland Heart and Metabolic Prevention Study (CHAMPS) | NCT03012022
Nitric oxide and peroxynitrite in health and disease. Physiol Rev (2007) 15.49
The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacol Rev (2006) 6.80
Therapeutic effects of xanthine oxidase inhibitors: renaissance half a century after the discovery of allopurinol. Pharmacol Rev (2006) 3.27
NO-independent stimulators and activators of soluble guanylate cyclase: discovery and therapeutic potential. Nat Rev Drug Discov (2006) 2.84
Soluble guanylate cyclase as an emerging therapeutic target in cardiopulmonary disease. Circulation (2011) 2.48
Role of the peroxynitrite-poly(ADP-ribose) polymerase pathway in human disease. Am J Pathol (2008) 2.15
Peroxynitrite is a major trigger of cardiomyocyte apoptosis in vitro and in vivo. Free Radic Biol Med (2006) 1.99
Role of superoxide, nitric oxide, and peroxynitrite in doxorubicin-induced cell death in vivo and in vitro. Am J Physiol Heart Circ Physiol (2009) 1.89
Role of poly(ADP-ribose) polymerase 1 (PARP-1) in cardiovascular diseases: the therapeutic potential of PARP inhibitors. Cardiovasc Drug Rev (2007) 1.86
Factors controlling cardiac myosin-isoform shift during hypertrophy and heart failure. J Mol Cell Cardiol (2007) 1.81
Endocannabinoids and cannabinoid receptors in ischaemia-reperfusion injury and preconditioning. Br J Pharmacol (2007) 1.65
Therapeutic applications of PARP inhibitors: anticancer therapy and beyond. Mol Aspects Med (2013) 1.62
S-nitrosylation: NO-related redox signaling to protect against oxidative stress. Antioxid Redox Signal (2006) 1.43
Role of oxidative-nitrosative stress and downstream pathways in various forms of cardiomyopathy and heart failure. Curr Vasc Pharmacol (2005) 1.42
Vascular dysfunction in aging: potential effects of resveratrol, an anti-inflammatory phytoestrogen. Curr Med Chem (2006) 1.35
Decreased age-related cardiac dysfunction, myocardial nitrative stress, inflammatory gene expression, and apoptosis in mice lacking fatty acid amide hydrolase. Am J Physiol Heart Circ Physiol (2007) 1.34
Role of peroxynitrite in the pathogenesis of cardiovascular complications of diabetes. Curr Opin Pharmacol (2006) 1.34
Redox regulation of mitochondrial function with emphasis on cysteine oxidation reactions. Redox Biol (2013) 1.28
Role of poly(ADP-ribose) polymerase-1 activation in the pathogenesis of diabetic complications: endothelial dysfunction, as a common underlying theme. Antioxid Redox Signal (2005) 1.28
The emerging role of the endocannabinoid system in cardiovascular disease. Semin Immunopathol (2009) 1.24
Beneficial effects of a novel ultrapotent poly(ADP-ribose) polymerase inhibitor in murine models of heart failure. Int J Mol Med (2006) 1.21
Oxidative stress in diabetes: implications for vascular and other complications. Int J Mol Sci (2013) 1.13
Interplay of oxidative, nitrosative/nitrative stress, inflammation, cell death and autophagy in diabetic cardiomyopathy. Biochim Biophys Acta (2014) 1.12
Xanthine oxidase inhibitor allopurinol attenuates the development of diabetic cardiomyopathy. J Cell Mol Med (2008) 1.05
Pharmacological inhibition of poly(ADP-ribose) polymerase inhibits angiogenesis. Biochem Biophys Res Commun (2006) 1.04
Dexrazoxane prevents doxorubicin-induced long-term cardiotoxicity and protects myocardial mitochondria from genetic and functional lesions in rats. Br J Pharmacol (2007) 1.02
Effects of statins on matrix metalloproteinases and their endogenous inhibitors in human endothelial cells. Naunyn Schmiedebergs Arch Pharmacol (2011) 0.98
The cGMP signaling pathway as a therapeutic target in heart failure with preserved ejection fraction. J Am Heart Assoc (2013) 0.98
Peroxynitrite induces HMGB1 release by cardiac cells in vitro and HMGB1 upregulation in the infarcted myocardium in vivo. Cardiovasc Res (2010) 0.98
Inhibition of matrix metalloproteinase-2 by PARP inhibitors. Biochem Biophys Res Commun (2009) 0.95
Exposure to inhaled particulate matter impairs cardiac function in senescent mice. Am J Physiol Regul Integr Comp Physiol (2008) 0.95
Drug-induced mitochondrial dysfunction and cardiotoxicity. Am J Physiol Heart Circ Physiol (2015) 0.94
Inhibition of matrix metalloproteinases prevents peroxynitrite-induced contractile dysfunction in the isolated cardiac myocyte. Br J Pharmacol (2007) 0.92
Levosimendan: from basic science to clinical practice. Heart Fail Rev (2008) 0.90
Single dose treatment with PARP-inhibitor INO-1001 improves aging-associated cardiac and vascular dysfunction. Exp Gerontol (2007) 0.89
Interactions between mitochondrial reactive oxygen species and cellular glucose metabolism. Arch Toxicol (2015) 0.88
Autophagy mechanism of right ventricular remodeling in murine model of pulmonary artery constriction. Am J Physiol Heart Circ Physiol (2011) 0.87
Protective effect of metalloporphyrins against cisplatin-induced kidney injury in mice. PLoS One (2014) 0.87
Cannabidiol Protects against Doxorubicin-Induced Cardiomyopathy by Modulating Mitochondrial Function and Biogenesis. Mol Med (2015) 0.87
Phosphocreatine interacts with phospholipids, affects membrane properties and exerts membrane-protective effects. PLoS One (2012) 0.85
Role of guanylate cyclase modulators in decompensated heart failure. Heart Fail Rev (2009) 0.84
Differential involvement of various sources of reactive oxygen species in thyroxin-induced hemodynamic changes and contractile dysfunction of the heart and diaphragm muscles. Free Radic Biol Med (2015) 0.84
Cardiac response to chronic intermittent hypoxia with a transition from adaptation to maladaptation: the role of hydrogen peroxide. Oxid Med Cell Longev (2012) 0.83
Pyrrolidine dithiocarbamate down-regulates vascular matrix metalloproteinases and ameliorates vascular dysfunction and remodelling in renovascular hypertension. Br J Pharmacol (2011) 0.83
Protective effect and mechanism of Ginkgo biloba extract-EGb 761 on STZ-induced diabetic cardiomyopathy in rats. Pharmacogn Mag (2014) 0.83
Soluble guanylate cyclase: a potential therapeutic target for heart failure. Heart Fail Rev (2013) 0.83
Trastuzumab alters the expression of genes essential for cardiac function and induces ultrastructural changes of cardiomyocytes in mice. PLoS One (2013) 0.82
Resveratrol attenuates azidothymidine-induced cardiotoxicity by decreasing mitochondrial reactive oxygen species generation in human cardiomyocytes. Mol Med Rep (2010) 0.82
Peroxynitrite is a key mediator of the cardioprotection afforded by ischemic postconditioning in vivo. PLoS One (2013) 0.81
Oxidative stress as a common mediator for apoptosis induced-cardiac damage in diabetic rats. Open Cardiovasc Med J (2008) 0.80
Conflicting effects of nitric oxide and oxidative stress in chronic heart failure: potential therapeutic strategies. Heart Fail Rev (2012) 0.80
The selective 5-LOX inhibitor 11-keto-β-boswellic acid protects against myocardial ischemia reperfusion injury in rats: involvement of redox and inflammatory cascades. Naunyn Schmiedebergs Arch Pharmacol (2013) 0.80
Peroxynitrite-driven mechanisms in diabetes and insulin resistance - the latest advances. Curr Med Chem (2011) 0.79
Role of nitroso radicals as drug targets in circulatory shock. Br J Pharmacol (2009) 0.78
Pathophysiological Role of Peroxynitrite Induced DNA Damage in Human Diseases: A Special Focus on Poly(ADP-ribose) Polymerase (PARP). Indian J Clin Biochem (2015) 0.76
Role of Oxidative Stress in Thyroid Hormone-Induced Cardiomyocyte Hypertrophy and Associated Cardiac Dysfunction: An Undisclosed Story. Oxid Med Cell Longev (2015) 0.76
Protective Effects of Carvedilol and Vitamin C against Azithromycin-Induced Cardiotoxicity in Rats via Decreasing ROS, IL1-β, and TNF-α Production and Inhibiting NF-κB and Caspase-3 Expression. Oxid Med Cell Longev (2016) 0.75
Febuxostat, a novel xanthine oxidoreductase inhibitor, improves hypertension and endothelial dysfunction in spontaneously hypertensive rats. Naunyn Schmiedebergs Arch Pharmacol (2016) 0.75
Modulation of Vascular ACE by Oxidative Stress in Young Syrian Cardiomyopathic Hamsters: Therapeutic Implications. J Clin Med (2016) 0.75
Pleiotropic effects of long-term monotherapy with rosuvastatin in dogs with moderate heart failure. Cardiology (2012) 0.75
Myeloperoxidase-Related Chlorination Activity Is Positively Associated with Circulating Ceruloplasmin in Chronic Heart Failure Patients: Relationship with Neurohormonal, Inflammatory, and Nutritional Parameters. Biomed Res Int (2015) 0.75
Combination of atorvastatin/coenzyme Q10 as adjunctive treatment in congestive heart failure: A double-blind randomized placebo-controlled clinical trial. ARYA Atheroscler (2014) 0.75
Alcohol Misuse and Kidney Injury: Epidemiological Evidence and Potential Mechanisms. Alcohol Res (2017) 0.75
Clozapine-induced cardiotoxicity in rats: Involvement of tumour necrosis factor alpha, NF-κβ and caspase-3. Toxicol Rep (2014) 0.75
The therapeutic potential of poly(ADP-ribose) polymerase inhibitors. Pharmacol Rev (2002) 5.92
Targeted deletion of matrix metalloproteinase-9 attenuates left ventricular enlargement and collagen accumulation after experimental myocardial infarction. J Clin Invest (2000) 4.79
Increased myocardial NADPH oxidase activity in human heart failure. J Am Coll Cardiol (2003) 3.73
Nitric oxide regulation of superoxide and peroxynitrite-dependent lipid peroxidation. Formation of novel nitrogen-containing oxidized lipid derivatives. J Biol Chem (1994) 3.64
Xanthine oxidoreductase and cardiovascular disease: molecular mechanisms and pathophysiological implications. J Physiol (2003) 3.19
Increased neuronal nitric oxide synthase-derived NO production in the failing human heart. Lancet (2004) 3.07
Matrix metalloproteinases: regulation and dysregulation in the failing heart. Circ Res (2002) 2.98
A matrix metalloproteinase induction/activation system exists in the human left ventricular myocardium and is upregulated in heart failure. Circulation (2000) 2.94
Plasma concentrations and genetic variation of matrix metalloproteinase 9 and prognosis of patients with cardiovascular disease. Circulation (2003) 2.89
Peroxynitrite is a major contributor to cytokine-induced myocardial contractile failure. Circ Res (2000) 2.80
New insights on oxidative stress and diabetic complications may lead to a "causal" antioxidant therapy. Diabetes Care (2003) 2.74
Potent metalloporphyrin peroxynitrite decomposition catalyst protects against the development of doxorubicin-induced cardiac dysfunction. Circulation (2003) 2.56
Nitric oxide, superoxide, and peroxynitrite in myocardial ischaemia-reperfusion injury and preconditioning. Br J Pharmacol (2003) 2.26
Intracellular action of matrix metalloproteinase-2 accounts for acute myocardial ischemia and reperfusion injury. Circulation (2002) 2.25
The role of poly(ADP-ribose) polymerase activation in the development of myocardial and endothelial dysfunction in diabetes. Diabetes (2002) 2.20
Nitric oxide and cardiac function: ten years after, and continuing. Circ Res (2003) 2.14
Clinical and biochemical results of the metalloproteinase inhibition with subantimicrobial doses of doxycycline to prevent acute coronary syndromes (MIDAS) pilot trial. Arterioscler Thromb Vasc Biol (2004) 2.07
Matrix metalloproteinase-2 contributes to ischemia-reperfusion injury in the heart. Circulation (2000) 2.01
NO/redox disequilibrium in the failing heart and cardiovascular system. J Clin Invest (2005) 1.94
Activation of matrix metalloproteinases by peroxynitrite-induced protein S-glutathiolation via disulfide S-oxide formation. J Biol Chem (2001) 1.80
Multiple pathways of peroxynitrite cytotoxicity. Toxicol Lett (2003) 1.77
Role of nitrosative stress and peroxynitrite in the pathogenesis of diabetic complications. Emerging new therapeutical strategies. Curr Med Chem (2005) 1.72
Cardiomyocyte overexpression of iNOS in mice results in peroxynitrite generation, heart block, and sudden death. J Clin Invest (2002) 1.70
Activation of poly(ADP-ribose) polymerase contributes to development of doxorubicin-induced heart failure. J Pharmacol Exp Ther (2002) 1.69
Nitric oxide's role in the heart: control of beating or breathing? Am J Physiol Heart Circ Physiol (2004) 1.60
Matrix metalloproteinase inhibition attenuates left ventricular remodeling and dysfunction in a rat model of progressive heart failure. Circulation (2001) 1.59
Protein nitration in cardiovascular diseases. Pharmacol Rev (2002) 1.58
Acute hyperglycemia induces nitrotyrosine formation and apoptosis in perfused heart from rat. Diabetes (2002) 1.48
Poly-ADP-ribose polymerase inhibition protects against myocardial and endothelial reperfusion injury after hypothermic cardiac arrest. J Thorac Cardiovasc Surg (2003) 1.44
Pharmacologic inhibition of poly(adenosine diphosphate-ribose) polymerase may represent a novel therapeutic approach in chronic heart failure. J Am Coll Cardiol (2002) 1.36
Endothelial cell activation in patients with decompensated heart failure. Circulation (2004) 1.33
A new, potent poly(ADP-ribose) polymerase inhibitor improves cardiac and vascular dysfunction associated with advanced aging. J Pharmacol Exp Ther (2004) 1.32
Early short-term treatment with doxycycline modulates postinfarction left ventricular remodeling. Circulation (2003) 1.31
Peroxynitrite-induced myocardial injury is mediated through matrix metalloproteinase-2. Cardiovasc Res (2002) 1.30
Oxidative stress during myocardial ischaemia and heart failure. Curr Pharm Des (2004) 1.28
Poly(ADP-Ribose) polymerase inhibition reduces reperfusion injury after heart transplantation. Circ Res (2002) 1.23
Enhanced NO and superoxide generation in dysfunctional hearts from endotoxemic rats. Am J Physiol Heart Circ Physiol (2002) 1.23
Regulation of matrix metalloproteinases by cytokines and reactive oxygen/nitrogen species in the myocardium. Heart Fail Rev (2004) 1.22
Poly(ADP-Ribose) polymerase promotes cardiac remodeling, contractile failure, and translocation of apoptosis-inducing factor in a murine experimental model of aortic banding and heart failure. J Pharmacol Exp Ther (2004) 1.22
Matrix metalloproteinase activation is an early event in doxorubicin-induced cardiotoxicity. Oncol Rep (2004) 1.18
Peroxynitrite decomposition catalysts prevent myocardial dysfunction and inflammation in endotoxemic rats. J Am Coll Cardiol (2004) 1.17
Diabetes-induced overexpression of endothelin-1 and endothelin receptors in the rat renal cortex is mediated via poly(ADP-ribose) polymerase activation. FASEB J (2003) 1.16
Peroxynitrite induced nitration and inactivation of myofibrillar creatine kinase in experimental heart failure. Cardiovasc Res (2001) 1.15
Poly(ADP-ribose) polymerase inhibitors. Curr Med Chem (2003) 1.12
Angiotensin II-mediated endothelial dysfunction: role of poly(ADP-ribose) polymerase activation. Mol Med (2004) 1.11
Poly(ADP-ribose) polymerase activation in the reperfused myocardium. Cardiovasc Res (2004) 1.08
Matrix metalloproteinase-2 mediates cytokine-induced myocardial contractile dysfunction. Cardiovasc Res (2003) 1.08
Endothelial dysfunction and peroxynitrite formation are early events in angiotensin-induced cardiovascular disorders. FASEB J (2000) 1.08
Ischaemia-reperfusion injury activates matrix metalloproteinases in the human heart. Eur Heart J (2004) 1.05
Peroxynitrite in myocardial ischemia-reperfusion injury. Heart Fail Rev (2002) 1.01
Selective matrix metalloproteinase inhibition with developing heart failure: effects on left ventricular function and structure. Circ Res (2003) 1.00
Poly(ADP-ribose) polymerase regulates myocardial calcium handling in doxorubicin-induced heart failure. Biochem Pharmacol (2005) 0.99
Increased expression of poly(ADP-ribose) polymerase-1 contributes to caspase-independent myocyte cell death during heart failure. Am J Physiol Heart Circ Physiol (2004) 0.99
A novel peroxynitrite decomposer catalyst (FP-15) reduces myocardial infarct size in an in vivo peroxynitrite decomposer and acute ischemia-reperfusion in pigs. Ann Thorac Surg (2002) 0.99
Absence of poly(ADP-ribose)polymerase-1 alters nuclear factor-kappa B activation and gene expression of apoptosis regulators after reperfusion injury. Mol Med (2003) 0.98
Cardiomyopathy in a murine model of AIDS: evidence of reactive nitrogen species and corroboration in human HIV/AIDS cardiac tissues. Cardiovasc Res (2003) 0.96
Doxycycline ameliorates ischemic and border-zone remodeling and endothelial dysfunction after myocardial infarction in rats. J Heart Lung Transplant (2004) 0.94
Role of poly(ADP-ribose) polymerase activation in endotoxin-induced cardiac collapse in rodents. Biochem Pharmacol (2002) 0.94
Nitrotyrosine and 8-isoprostane formation indicate free radical-mediated injury in hearts of patients subjected to cardioplegia. J Thorac Cardiovasc Surg (2003) 0.93
Role of myocardial inducible nitric oxide synthase in contractile dysfunction and beta-adrenergic hyporesponsiveness in rats with experimental volume-overload heart failure. Circulation (2002) 0.93
Poly(ADP-ribose) polymerase contributes to the development of myocardial infarction in diabetic rats and regulates the nuclear translocation of apoptosis-inducing factor. J Pharmacol Exp Ther (2004) 0.92
Effects of peroxynitrite on isolated cardiac trabeculae: selective impact on myofibrillar energetic controllers. Biochimie (2003) 0.90
Contribution of vascular NAD(P)H oxidase to endothelial dysfunction in heart failure and the therapeutic effects of HMG-CoA reductase inhibitor. Circ J (2004) 0.89
Inducible nitric oxide synthase-derived superoxide contributes to hypereactivity in small mesenteric arteries from a rat model of chronic heart failure. Br J Pharmacol (2000) 0.89
Differential regulation of activator protein-1 and heat shock factor-1 in myocardial ischemia and reperfusion injury: role of poly(ADP-ribose) polymerase-1. Am J Physiol Heart Circ Physiol (2003) 0.89
Time course of nitric oxide, peroxynitrite, and antioxidants in the endotoxemic heart. Crit Care Med (2002) 0.87
Influence of peroxynitrite on energy metabolism and cardiac function in a rat ischemia-reperfusion model. Am J Physiol Heart Circ Physiol (2003) 0.86
Peroxynitrite-induced inhibition and nitration of cardiac myofibrillar creatine kinase. Biochimie (2002) 0.86
An inhibitor of poly (ADP-ribose) synthetase activity reduces contractile dysfunction and preserves high energy phosphate levels during reperfusion of the ischaemic rat heart. Br J Pharmacol (1999) 0.85
M40403 prevents myocardial injury induced by acute hyperglycaemia in perfused rat heart. Eur J Pharmacol (2004) 0.84
Beneficial effects of poly (ADP-ribose) polymerase inhibition against the reperfusion injury in heart transplantation. Free Radic Res (2003) 0.83
Immunocytochemical evidence for inducible nitric oxide synthase and cyclooxygenase-2 expression with nitrotyrosine formation in human hibernating myocardium. Basic Res Cardiol (2002) 0.83
Leukocyte-depleted terminal blood cardioplegia provides superior myocardial protective effects in association with myocardium-derived nitric oxide and peroxynitrite production for patients undergoing prolonged aortic crossclamping for more than 120 minutes. J Thorac Cardiovasc Surg (2003) 0.81
Lethal effect of cytokine-induced nitric oxide and peroxynitrite on cultured rat cardiac myocytes. J Mol Cell Cardiol (2002) 0.81
Role of poly(ADP-ribose) polymerase activation in the pathogenesis of cardiopulmonary dysfunction in a canine model of cardiopulmonary bypass. Eur J Cardiothorac Surg (2004) 0.80
Perindopril effect on uncoupling protein and energy metabolism in failing rat hearts. Hypertension (2002) 0.79
Repetitive myocardial stunning in pigs is associated with an increased formation of reactive nitrogen species. Heart (2002) 0.78
Poly(ADP-ribose) polymerase activation and cell injury in the course of rat heart heterotopic transplantation. Free Radic Res (2002) 0.77
Nitric oxide and peroxynitrite in health and disease. Physiol Rev (2007) 15.49
The therapeutic potential of poly(ADP-ribose) polymerase inhibitors. Pharmacol Rev (2002) 5.92
Poly(ADP-ribose) polymerase and the therapeutic effects of its inhibitors. Nat Rev Drug Discov (2005) 4.61
Enhancing the quality of life of dementia caregivers from different ethnic or racial groups: a randomized, controlled trial. Ann Intern Med (2006) 4.13
Long-term mortality and quality of life after prolonged mechanical ventilation. Crit Care Med (2004) 3.36
Therapeutic effects of xanthine oxidase inhibitors: renaissance half a century after the discovery of allopurinol. Pharmacol Rev (2006) 3.27
Early predictors of outcome in comatose survivors of ventricular fibrillation and non-ventricular fibrillation cardiac arrest treated with hypothermia: a prospective study. Crit Care Med (2008) 3.14
Inhibition of GAPDH activity by poly(ADP-ribose) polymerase activates three major pathways of hyperglycemic damage in endothelial cells. J Clin Invest (2003) 2.95
Patients' recollections of stressful experiences while receiving prolonged mechanical ventilation in an intensive care unit. Crit Care Med (2002) 2.91
A motivational theory of life-span development. Psychol Rev (2010) 2.89
Predictors of awakening from postanoxic status epilepticus after therapeutic hypothermia. Neurology (2009) 2.83
Pharmacological inhibition of CB1 cannabinoid receptor protects against doxorubicin-induced cardiotoxicity. J Am Coll Cardiol (2007) 2.81
Effect of multicomponent interventions on caregiver burden and depression: the REACH multisite initiative at 6-month follow-up. Psychol Aging (2003) 2.70
Depression and Bipolar Support Alliance consensus statement on the unmet needs in diagnosis and treatment of mood disorders in late life. Arch Gen Psychiatry (2003) 2.70
Hydrogen sulfide is an endogenous stimulator of angiogenesis. Proc Natl Acad Sci U S A (2009) 2.66
Potent metalloporphyrin peroxynitrite decomposition catalyst protects against the development of doxorubicin-induced cardiac dysfunction. Circulation (2003) 2.56
From evidence to clinical practice: effective implementation of therapeutic hypothermia to improve patient outcome after cardiac arrest. Crit Care Med (2006) 2.48
Review and meta-analysis of couple-oriented interventions for chronic illness. Ann Behav Med (2010) 2.47
The Resources for Enhancing Alzheimer's Caregiver Health (REACH): project design and baseline characteristics. Psychol Aging (2003) 2.36
Nitric oxide, superoxide, and peroxynitrite in myocardial ischaemia-reperfusion injury and preconditioning. Br J Pharmacol (2003) 2.26
Intracellular action of matrix metalloproteinase-2 accounts for acute myocardial ischemia and reperfusion injury. Circulation (2002) 2.25
The course of functional decline in older people with persistently elevated depressive symptoms: longitudinal findings from the Cardiovascular Health Study. J Am Geriatr Soc (2005) 2.20
The role of poly(ADP-ribose) polymerase activation in the development of myocardial and endothelial dysfunction in diabetes. Diabetes (2002) 2.20
Is it beneficial to involve a family member? A meta-analysis of psychosocial interventions for chronic illness. Health Psychol (2004) 2.14
Adaptive self-regulation of unattainable goals: goal disengagement, goal reengagement, and subjective well-being. Pers Soc Psychol Bull (2003) 2.13
Isolated heart perfusion according to Langendorff---still viable in the new millennium. J Pharmacol Toxicol Methods (2006) 2.06
Trust in the health care system and the use of preventive health services by older black and white adults. Am J Public Health (2008) 2.04
Intra-mitochondrial poly(ADP-ribosylation) contributes to NAD+ depletion and cell death induced by oxidative stress. J Biol Chem (2003) 2.04
The vasodilatory response of skin microcirculation to local heating is subject to desensitization. Microcirculation (2009) 2.02
Poly(ADP-ribose) polymerase is involved in the development of diabetic retinopathy via regulation of nuclear factor-kappaB. Diabetes (2004) 2.02
Peroxynitrite is a major trigger of cardiomyocyte apoptosis in vitro and in vivo. Free Radic Biol Med (2006) 1.99
Novel phenanthridinone inhibitors of poly (adenosine 5'-diphosphate-ribose) synthetase: potent cytoprotective and antishock agents. Crit Care Med (2002) 1.97
Family caregivers' strains: comparative analysis of cancer caregiving with dementia, diabetes, and frail elderly caregiving. J Aging Health (2008) 1.94
Prevalence and outcomes of caregiving after prolonged (> or =48 hours) mechanical ventilation in the ICU. Chest (2004) 1.91
Role of superoxide, nitric oxide, and peroxynitrite in doxorubicin-induced cell death in vivo and in vitro. Am J Physiol Heart Circ Physiol (2009) 1.89
Role of poly(ADP-ribose) polymerase 1 (PARP-1) in cardiovascular diseases: the therapeutic potential of PARP inhibitors. Cardiovasc Drug Rev (2007) 1.86
Risk factors for potentially harmful informal caregiver behavior. J Am Geriatr Soc (2005) 1.81
Titin is a target of matrix metalloproteinase-2: implications in myocardial ischemia/reperfusion injury. Circulation (2010) 1.80
Role of poly(ADP-ribose) polymerase activation in diabetic neuropathy. Diabetes (2004) 1.79
Body temperature regulation and outcome after cardiac arrest and therapeutic hypothermia. Resuscitation (2011) 1.78
CB2-receptor stimulation attenuates TNF-alpha-induced human endothelial cell activation, transendothelial migration of monocytes, and monocyte-endothelial adhesion. Am J Physiol Heart Circ Physiol (2007) 1.77
Caregiving behavior is associated with decreased mortality risk. Psychol Sci (2009) 1.76
Caregiver-specific outcomes in antidementia clinical drug trials: a systematic review and meta-analysis. J Am Geriatr Soc (2005) 1.75
Role of nitrosative stress and peroxynitrite in the pathogenesis of diabetic complications. Emerging new therapeutical strategies. Curr Med Chem (2005) 1.72
Effect of an in-home occupational and physical therapy intervention on reducing mortality in functionally vulnerable older people: preliminary findings. J Am Geriatr Soc (2006) 1.71
Cardiac and metabolic effects of hypothermia and inhaled hydrogen sulfide in anesthetized and ventilated mice. Crit Care Med (2010) 1.70
Cardiomyocyte overexpression of iNOS in mice results in peroxynitrite generation, heart block, and sudden death. J Clin Invest (2002) 1.70
Preparedness for the death of a loved one and mental health in bereaved caregivers of patients with dementia: findings from the REACH study. J Palliat Med (2006) 1.69
Matrix metalloproteinase-2 (MMP-2) is present in the nucleus of cardiac myocytes and is capable of cleaving poly (ADP-ribose) polymerase (PARP) in vitro. FASEB J (2004) 1.69
Patient-specific, time-varying predictors of post-ICU informal caregiver burden: the caregiver outcomes after ICU discharge project. Chest (2009) 1.69
Left ventricular pressure-volume relationship in a rat model of advanced aging-associated heart failure. Am J Physiol Heart Circ Physiol (2004) 1.67
Benefit-finding in the cancer caregiving experience. Psychosom Med (2007) 1.67
Informal caregiver burden among survivors of prolonged mechanical ventilation. Am J Respir Crit Care Med (2006) 1.64
Flagellin from gram-negative bacteria is a potent mediator of acute pulmonary inflammation in sepsis. Shock (2003) 1.64
Role for nitrosative stress in diabetic neuropathy: evidence from studies with a peroxynitrite decomposition catalyst. FASEB J (2004) 1.64
The association of race and socioeconomic status with cardiovascular disease indicators among older adults in the health, aging, and body composition study. J Gerontol B Psychol Sci Soc Sci (2002) 1.58
Effects of intravenous sulfide during resuscitated porcine hemorrhagic shock*. Crit Care Med (2012) 1.58
Cannabidiol attenuates cardiac dysfunction, oxidative stress, fibrosis, and inflammatory and cell death signaling pathways in diabetic cardiomyopathy. J Am Coll Cardiol (2010) 1.56
Interpersonal effects of suffering in older adult caregiving relationships. Psychol Aging (2009) 1.56
Degradation of myosin light chain in isolated rat hearts subjected to ischemia-reperfusion injury: a new intracellular target for matrix metalloproteinase-2. Circulation (2005) 1.56
Depression and distress predict time to cardiovascular disease in dementia caregivers. Health Psychol (2007) 1.55
Caregiving at the end of life. J Palliat Med (2006) 1.54
Transitions in spousal caregiving. Gerontologist (2003) 1.54
Cannabidiol attenuates high glucose-induced endothelial cell inflammatory response and barrier disruption. Am J Physiol Heart Circ Physiol (2007) 1.54
Clinical research and the stages of dying. Omega (Westport) (1974) 1.53
Immunomodulatory and neuroprotective effects of inosine. Trends Pharmacol Sci (2004) 1.53
Using a new taxonomy to combine the uncombinable: integrating results across diverse interventions. Psychol Aging (2003) 1.53
Intranuclear localization of apoptosis-inducing factor (AIF) and large scale DNA fragmentation after traumatic brain injury in rats and in neuronal cultures exposed to peroxynitrite. J Neurochem (2002) 1.52
The Life Engagement Test: assessing purpose in life. J Behav Med (2006) 1.50
Financial exploitation and psychological mistreatment among older adults: differences between African Americans and non-African Americans in a population-based survey. Gerontologist (2010) 1.49
Aldose reductase inhibition counteracts oxidative-nitrosative stress and poly(ADP-ribose) polymerase activation in tissue sites for diabetes complications. Diabetes (2005) 1.49
The adenosine A3 receptor agonist, N6-(3-iodobenzyl)-adenosine-5'-N-methyluronamide, is protective in two murine models of colitis. Eur J Pharmacol (2003) 1.48
Effects of FP15, a peroxynitrite decomposition catalyst on cardiac and pulmonary function after cardiopulmonary bypass. Eur J Cardiothorac Surg (2012) 1.48
Improving quality of life in men with prostate cancer: a randomized controlled trial of group education interventions. Health Psychol (2003) 1.48
Clinical perspectives of PARP inhibitors. Pharmacol Res (2005) 1.46
Parenteral administration of glipizide sodium salt, an inhibitor of adenosine triphosphate-sensitive potassium channels, prolongs short-term survival after severe controlled hemorrhage in rats. Crit Care Med (2003) 1.46
Mesenteric injury after cardiopulmonary bypass: role of poly(adenosine 5'-diphosphate-ribose) polymerase. Crit Care Med (2004) 1.46
Identification of conserved domains in Salmonella muenchen flagellin that are essential for its ability to activate TLR5 and to induce an inflammatory response in vitro. J Biol Chem (2003) 1.46
Peroxynitrite-induced cytotoxicity: mechanism and opportunities for intervention. Toxicol Lett (2003) 1.45
Patterns of depressive symptoms in caregivers of mechanically ventilated critically ill adults from intensive care unit admission to 2 months postintensive care unit discharge: a pilot study. Crit Care Med (2012) 1.45
Resistance to acute septic peritonitis in poly(ADP-ribose) polymerase-1-deficient mice. Shock (2002) 1.44
Poly-ADP-ribose polymerase inhibition protects against myocardial and endothelial reperfusion injury after hypothermic cardiac arrest. J Thorac Cardiovasc Surg (2003) 1.44
Preparing family caregivers for death and bereavement. Insights from caregivers of terminally ill patients. J Pain Symptom Manage (2008) 1.42
The prognostic significance of inspiratory capacity in pulmonary arterial hypertension. Respiration (2014) 1.41
An evidence-based medicine elective course to improve student performance in advanced pharmacy practice experiences. Am J Pharm Educ (2011) 1.41
Postresuscitation administration of doxycycline preserves cardiac contractile function in hypoxia-reoxygenation injury of newborn piglets*. Crit Care Med (2014) 1.40
Sepsis up-regulates the expression of connexin 40 in rat aortic endothelium. Crit Care Med (2005) 1.40
Matrix metalloproteinase-2 and myocardial oxidative stress injury: beyond the matrix. Cardiovasc Res (2009) 1.39
Cannabinoid-2 receptor agonist HU-308 protects against hepatic ischemia/reperfusion injury by attenuating oxidative stress, inflammatory response, and apoptosis. J Leukoc Biol (2007) 1.39
Pulse wave analysis of aortic pressure: diastole should also be considered. J Hypertens (2013) 1.39
Prevalence and correlates of anxiety symptoms in well-functioning older adults: findings from the health aging and body composition study. J Am Geriatr Soc (2003) 1.38
Gender differences in the endotoxin-induced inflammatory and vascular responses: potential role of poly(ADP-ribose) polymerase activation. J Pharmacol Exp Ther (2005) 1.37
Pharmacologic inhibition of poly(adenosine diphosphate-ribose) polymerase may represent a novel therapeutic approach in chronic heart failure. J Am Coll Cardiol (2002) 1.36